For families battling Duchenne, a rare and fatal muscle-wasting disease, this decision isn’t just bureaucratic—it’s a lifeline. The FDA’s initial resistance sparked outrage, but their reversal shows how patient advocacy and public pressure can shape drug approvals. It also signals a potential shift in how regulators weigh risks for diseases with few treatment options.

After our editorial, the agency relents to allow a Duchenne treatment.

The FDA reversed its stance on a Duchenne muscular dystrophy treatment after public pushback, including an editorial. This means Sarepta Therapeutics can move forward with a therapy that could help patients with this devastating disease—a win for advocates who argued the benefits outweighed the risks.

On Sarepta, a Welcome FDA Reversal

Was this article worth reading? Share it

Ready to build your own newsroom?